Keywords:
Lung, CT, Stereotactic radiotherapy, Cancer
Authors:
C. Chong, H. Tan, C. Harper, R. Chee, E. Ng, S. Mincham, C. Vaz, E. Leong, T. Lim
DOI:
10.26044/ranzcr2022/R-0088
Results
Patient Characteristics
A total of 93 patients were included in the analysis and the mean follow up was 30.3 (range, 1-99) months. SABR doses ranged from 48 - 60Gy in 4 -10 fractions and the mean biological equivalent dose (BED10) was 105.3Gy.
The median age was 77 (range, 54-94) years. There were 50 patients with tumour size less than 2cm and 42 patients with tumour size > 2cm. Majority of histology subtype was adenocarcinoma (n=57).
Local Control and Overall Survival
The 1, 2 and 3-year LC were 92.6%, 86.8% and 81.3% respectively.
Further univariate analysis on age, smoking status, size of tumour, dose and histology on survival did not show any significant correlation. Higher BED however on competing risk analysis was associated with a trend toward better LC (p=0.031).
The median overall survival was 75.8 (95% CI, 66 - 85.7) months; 1, 2 and 3-year OS were 89.6%, 84.5% and 81%, respectively.
The median progression free survival was 54.4 (95% CI, 45.7 - 63) months; 1, 2 and 3-year PFS were 88.6%, 71.7%, 56.2%, respectively. Figure 2 and 3 illustrates the overall survival and local control for our cohort.
Toxicities
There were 2 cases of >grade 3 toxicities; rib fractures (2.1%). Sixteen cases of grade 2 pneumonitis (16.1%) and 3 cases of grade 2 chest wall pain (3.3%). Further univariate analysis on age, smoking status, size of tumour, dose and histology on survival did not show any significant correlation.